Literature DB >> 2532874

Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing.

D R Guay1, W M Awni, C E Halstenson, M T Kenny, W F Keane, G R Matzke.   

Abstract

The pharmacokinetics of teicoplanin after single 6-mg/kg intravenous and intraperitoneal doses were studied in five noninfected patients undergoing continuous ambulatory peritoneal dialysis. Biological samples were assayed for teicoplanin content by a microbiological assay technique. Terminal disposition half-life (266.4 +/- 51.9 h [mean +/- standard error of the mean]) was prolonged and total body clearance (0.040 +/- 0.004 ml/min per kg) was reduced compared with values previously reported in subjects with normal renal function. The volume of distribution at steady state (1.15 +/- 0.19 liters/kg) was higher than values previously reported in subjects with normal renal function (0.56 to 0.72 liter/kg). Peritoneal dialysis clearance (0.007 +/- 0.001 ml/min per kg) accounted for only 16.1% of total body clearance. The absolute systemic bioavailability of teicoplanin after intraperitoneal administration was 81.5 +/- 10.7%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2532874      PMCID: PMC172806          DOI: 10.1128/AAC.33.11.2012

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp.

Authors:  S Somma; L Gastaldo; A Corti
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

2.  In vitro antistaphylococcal activity of teicoplanin and ciprofloxacin in peritoneal dialysis effluent.

Authors:  D Guay; R Klicker; T Pence; P Peterson
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

3.  Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis.

Authors:  G L Traina; M G Gentile; G Fellin; R Rosina; L Cavenaghi; G Buniva; M Bonati
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

5.  Pharmacokinetics of teicoplanin in man after intravenous administration.

Authors:  G L Traina; M Bonati
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

Review 6.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

7.  Teicoplanin pharmacokinetics in patients with chronic renal failure.

Authors:  M Bonati; G L Traina; G Villa; A Salvadeo; M G Gentile; G Fellin; R Rosina; L Cavenaghi; G Buniva
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

8.  Teicoplanin pharmacokinetics and bioavailability during peritoneal dialysis.

Authors:  R J Brouard; J E Kapusnik; J G Gambertoglio; P Y Schoenfeld; M Sachdeva; K Freel; T N Tozer
Journal:  Clin Pharmacol Ther       Date:  1989-06       Impact factor: 6.875

9.  Teicoplanin, its pharmacokinetics, blister and peritoneal fluid penetration.

Authors:  R Wise; I A Donovan; C A McNulty; R Waldron; J M Andrews
Journal:  J Hosp Infect       Date:  1986-03       Impact factor: 3.926

10.  Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin.

Authors:  H Lagast; P Dodion; J Klastersky
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

View more
  3 in total

1.  Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis.

Authors:  Selma Tobudic; Peter Matzneller; Brigitte Stoiser; Judith Maria Wenisch; Markus Zeitlinger; Andreas Vychytil; Walter Jaeger; Michaela Boehmdorfer; Gottfried Reznicek; Heinz Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

2.  An Open, Randomized, Single-Center, Crossover Pharmacokinetic Study of Meropenem after Intraperitoneal and Intravenous Administration in Patients Receiving Automated Peritoneal Dialysis.

Authors:  Martin Wiesholzer; Petra Pichler; Gottfried Reznicek; Michaela Wimmer; Manuel Kussmann; Peter Balcke; Heinz Burgmann; Markus Zeitlinger; Wolfgang Poeppl
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  Therapeutic Drug Level Monitoring of Teicoplanin in Korean Pediatric Patients with Normal versus Impaired Renal Function.

Authors:  Joon Sik Choi; Jong Min Kim; Dongsub Kim; Si Ho Kim; Heeyeon Cho; Hyung Doo Park; Soo Youn Lee; Cheol In Kang; Yae Jean Kim
Journal:  J Korean Med Sci       Date:  2020-11-30       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.